These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26503519)

  • 1. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
    Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
    BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource use and cost of hepatitis C-related care.
    Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
    Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
    Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
    [TBL] [Abstract][Full Text] [Related]  

  • 4.  The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
    Méndez-Sánchez N
    Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
    J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
    Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
    CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
    Mantravadi S
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
    Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
    Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma.
    Saab S; Jimenez M; Fong T; Wu C; El Kabany M; Tong MJ
    Exp Clin Transplant; 2016 Feb; 14(1):66-71. PubMed ID: 26581477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Hepatitis C Infection.
    Stepanova M; Younossi ZM
    Clin Liver Dis; 2017 Aug; 21(3):579-594. PubMed ID: 28689595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Hill LA; Delmonte RJ; Andrews B; Richards L; Soto R; Collier S; Kuo A; Cachay E
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1378-1383. PubMed ID: 29975243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma.
    Hoshida Y; Shiratori Y; Omata M
    Liver; 2002 Dec; 22(6):479-85. PubMed ID: 12445173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
    Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
    Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
    Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
    Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.